This research focuses on lung malformations detected in fetuses during prenatal ultrasound exams. Pathogenic mechanisms of these rare malformations are poorly understood. Improved knowledge is needed, to give families better information, and to better standardize treatment decisions The main goal is to better predict neonatal complications associated with these malformations, by identifying key predictive markers during the fetal period. To achieve this objective, it is planned to include 400 pregnant women with prenatal diagnosis of pulmonary malformation in 45 health centers in France. This is the largest study on this topic at the international level.
The main objective of the study is to develop a prognostic model for estimating the risk of neonatal respiratory distress in children with prenatally diagnosed congenital pulmonary malformation. The study will be offered to all pregnant women referred to a Center for Prenatal Diagnosis (CPD), due to the identification of a congenital lung malformations in the fetus. This study does not induce any changes in clinical and therapeutic monitoring proposed by the team in charge of the mother. At inclusion, and at each prenatal evaluation, prenatal parameters are entered in an e-CRF. In an effort to minimize any potential intra- and interoperator variability in malformation measurements over time, this study includes a standardized and centralized evaluation of ultrasound and MRI (if available) acquisitions of volume measurements. When the place of delivery is determined, a contact is made before birth with the teams (maternity, neonatology, intensive care unit), so that neonatal data are also collected prospectively. A phone call to the family is planned for the end of the first postnatal month, to identify any respiratory event that would have occurred between returning home after childbirth and the first month. The routine follow-up of these children is then ensured in accordance with current national recommendations, in conjunction with the reference centers for rare respiratory diseases in children (28 university hospitals, spread across all regions of France). A telephone survey every 6 months with the referring physician in this specialized center or, alternatively, with the family, will collect clinical outcome until the age of 2 years. If a surgical intervention is planned within this interval, consent to collect part of the surgical specimen for research purposes will be solicited. This tissue will be immediately frozen at -80 ° C, to allow laser microdissection and DNA extraction from epithelial cells lining the malformation (Inserm U955). Frozen tissue will be conserved at the biobank of Necker-Enfants Malades.
Study Type
OBSERVATIONAL
Enrollment
436
Hôpital Necker - Enfants Malades
Paris, France
Respiratory distress
Respiratory distress at birth is defined by a breathing frequency \> 60/min, or by the presence of chest retraction signs (Silverman score greater than or equal to 2). At least one of these signs must be persistent at 15' of life
Time frame: At Birth of the child
Necessity of antenatal treatment
Thoracic drainage, amniotic drainage, corticosteroids
Time frame: At Birth of the child
Therapeutic abortion - fetal death
Time frame: At Birth of the child
Severe respiratory distress
Severe respiratory distress at birth will be defined by the presence of at least one of the following parameters: persistent need at 15' of supplemental oxygen; Persistent need at 15' for a ventilatory support (non-invasive or invasive); neonatal death
Time frame: At Birth of the child
Identification of KRAS mutation
PCR analysis of known K-RAS mutations in codons 12 and 13
Time frame: 2 years
Level in delta Forskoline/IBMX Short Circuit Current (µA/cm2)
CFTR activity evaluation
Time frame: 2 years
CFTR gene expression
quantitative PCR
Time frame: 2 years
CFTR protein expression
immunohistochemistry
Time frame: 2 years
Basal short circuit current : Isc Basal
Time frame: 2 years
Effects of other potentiators on CFTR activity : ΔGenistein, ΔVX-770
Time frame: 2 years
Inhibition of CFTR (inh-172) : ΔInh-172
Time frame: 2 years
Response to ENaC inhibitors : ΔAmiloride, Δbenzamil
Time frame: 2 years
Activation of Calcium Dependant Channels : ΔUTP
Time frame: 2 years
Inhibition of SLC26A9 : ΔGlyH-101
Time frame: 2 years
Response to inhibitors of basolateral K+ secretion : ΔBarium ; ΔChromanol
Time frame: 2 years
Secretion of HCO3- in response to forskoline : Δ HCO3- primary culture
Time frame: 2 years
Gene expression of other channels : ENaC, SLC26A9, CaCC, KVLQT1 and KCa3.1
quantitative PCR
Time frame: 2 years
Protein expression of other channels : ENaC, SLC26A9, CaCC, KVLQT1 and KCa3.1
immunohistochemistry
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.